Benitec Biopharma Inc. · NASDAQ:BNTC
Benitec Biopharma — Benitec — AusBiotech National Conference 2006
21 slides from Benitec Biopharma's conference presentation, Nov 27, 2006
Slide 1: Business Partnering Presentation
Benitec Ltd (ASX:BLT) Business Partnering Presentation AusBiotech National Conference 227 November 2006
Slide 2: Benitec Corporate Overview
Benitec (ASX:BLT) Corporate Overview = Benitec are pioneers in the RNA interference (RNAi) field and are using proprietary technologies to develop RNAi drugs for unmet medical needs such as HIV and Hepatitis C (HCV) in mid 2006 the new Board and advisory team commenced a strategic review to refocus
Slide 3: Corporate Overview
Corporate Overview = ® Pioneers in RNAI since 1997 ® Seminal patents in DNA-directed RNA interference (ddRNAji) technology ® Multiple licensees for commercial and therapeutic uses of RNAI ® Focused on developing treatments for commercially attractive, major, life-threatening diseases ® Listed on the
Slide 4: RNAi Therapeutics - A Disruptive New Platform
RNAi Therapeutics- A Disruptive New Platform = —» Function RNAi Small Molecules Antibodies * Target: RNA * Challenge: Delivery * Advantage: Allows facile targeting of both “druggable and “non-druggable” regions of disease-causing genes (coding for RNA or protein) 8 * Target: Protein * Challenge: Spe
Slide 5: Mechanism of RNA interference (RNAi)
Mechanism of RNA interference (RNAi) ~) siRNA or Activated RNAi # Natural mechanism ® Rapidly deployed @ Highly specific ® Catalytic Target Binding Target Destruction | ‘9. pom
Slide 6: Advantages of ddRNAi technology
Advantages of ddRNAi technology ) Compared with alternative gene silencing technologies eg antisense and siRNA the Benitec ddRNAi technology has the following advantages: ~ Lower cost and ease of preparation ~ More versatile delivery options ~ The ability to silence genes in whole organisms (transge
Slide 7: RNAi Market opportunity
RNAi Market opportunity ) *The RNAi market achieved global sales of just over USD$1bn in 2004 *Projected to reach USD$2.5bn by 2010 «Competitive dynamic market environment Figure 1 Estienated annual worldwide revenues fron RMA: and market segments. ta} Although the market for RNAI ig new anc relativ
Slide 8: Market Reward for RNAi
Market Reward for RNAi Benitec, Alnylam, and Sirna were featured on a BIO 2006 panel discussion ~ moderated by a Senior Analyst at Piper Jaffray as the leading companies worldwide in intellectual property and development of RNAi. Alnylam Pharmaceuticals Sirna Therapeutics * Current market cap US$654
Slide 9: Intellectual Property
intellectual Property An industry-leading patent portfolio in RNAi® DNA-directed RNAi in plants DNA-directed RNAi in tissue RNAi in mouse model of human disease (Graham et al.) “culture and mammals (McCaffrey and Kay) (Graham et al.) | Plant . co-suppression RNAi in nematodes. RNAi in Drosophila and
Slide 10: Benitec IP Position
Benitec IP Position ) Extract from Companies & Markets, Jain PharmaBiotech, August 2006 RNAI patents - Among the companies, Alnylam and Benitec have strong patent positions. * On 5 June 2003, Benitec Lid was granted its core technology patents in the US and the UK. * These patents, with priority dat
Slide 11: Licensees and Strategic Partners
Licensees and Strategic Partners ) * Therapeutic Use of ddRNAI fy if lj | rey ~ Tacere Therapeutics vi) A AYIA) ~ Alnylam Pharmaceuticals COMEUMATREX, — CombiMatrix Diiseswar the possibtities ~ Revivicor * Research Reagent or Transgenic Animal Product Development and Sales ~ Sigma-Aldrich Poa . . @
Slide 12: Benitec Capital Structure
Benitec Capital Structure Shares outstanding Share price as of 17 Nov 2006 Market capitalization Options/warrants outstanding Fully diluted shares BENITEC as of 17-Nov-2006 T 188.47 M A$0.073 A$13.75M Splits: ¥ 0.25 0.20 0.45 o.10 Ce ee o = = Millions a jute fl osu wal tua a \ Copyright 2006 Yahoo!
Slide 13: RNAi Drug Development Strategy
RNAi Drug Development Strategy ) Sequence-based, broad specificity therapeutics ® Select RNAi targets quickly to cover most of patient population (RNAI advantage over small molecule) Prevent generation of drug-resistant diseases ® Combination of multiple drugs in a single treatment (ddRNAi advantage
Slide 14: HIV/AIDS Stem Cell Program
HIV/AIDS Stem Cell Program = * Molecular Targets ~ HIV genome — cell-surface receptor ~ replication machinery ¢ Data published in Nature Reviews, PNAS, and Molecular Therapy * Clinical Development Partner: City of Hope ~ Principal Investigator: John Rossi, Ph.D. ~ Clinical Investigator: John Zaia, M
Slide 15: HIV Program - Path to Clinic
HIV Program- Path to Clinic = * Stem Cell Therapy For HIV/AIDS Lymphoma ~ HIV/AIDS Lymphoma manufactured at City of Hope ~ RAC submission reviewed at the NIH on 21 September 2005 ~ Pre-IND meeting held on 17 October 2005 ~ Single site Phase 1 trial to be performed ait the City of Hope Medical Center
Slide 16: AIDS / lymphoma clinical trial design
AIDS / lymphoma clinical trial design ) Stem-cell Apheresis PF ere’ enrichment es Healthy HIV positive or chemo-responsive AIBS lymphoma . Lentiviral-mediated patient transduction of CD34’ stem cells GCSF Pool and infuse into ; patient after 5-day chemotherapy ee Patient follow-up for marking Hager
Slide 17: HCV Program
HCV Program = Molecular Target: Hepatitis C Virus genome Data published in Nature and Nature Biotech RNAi Therapeutics — Multi-targeting to prevent viral escape ~ “Cocktail” in one drug Licensed to Tacere Therapeutics Inc Sept 06 Structural Proteins Non-Structural Proteins
Slide 18: Recovery plan for 2006
Recovery pian for 2006 = Refocus business with move to lower cost model of value creation with co-investment and/or licensing to bring in additional revenues Complete a successful capital raising to fund turnaround Re-establish presence in Australia and appoint Australian based management team Comme
Slide 19: Risk and Mitigation
Risk and Mitigation ) * Risks ~ UPSTO re-examination and Nucleonic litigation ~ Cash position ° Mitigation ~ Capital raising ~ Low cost model ~ Continuing to seek advice from patent attorneys and provide input to ensure the strategy for prosecution of the core ddRNAi patent applications optimizes th
Slide 20: Compelling opportunity for investment
Compelling opportunity for investment ) Opportunity for investors — dynamic area ~ Undervalued ~ Nobel Prize Fire and Mello — validation of science ~ Merck purchase of Sirna for 1.1B 2x market cap — validation by business Strong IP position ~ Global rights to human therapeutics High profile license
Slide 21: Thank you
Thank you Sue MacLeman Level 16, 356 Collins St Melbourne Vic 3000 +67 3 437211200 smacleman@benitec.com i www.benitec.com